Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-1647 in Healthy Japanese Adults
NCT05105048Phase 1Completed
- Sponsor
- Moderna Inc
- Start
- Nov 2021
- Primary completion
- Aug 2023
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in cytomegalovirus infection (CMV) comparing mRNA-1647 with Placebo (2 arms). Primary endpoints: Number of Participants With Solicited Local and Systemic Adverse Reactions, Number of Participants With Unsolicited Adverse Events and 1 more. Started Nov 2021; status: completed.
02
Drugs
mRNA-1647
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT05105048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105048.